Myocardial viability imaging and revascularization in chronic ischemic left ventricular systolic dysfunction

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 1, 2010, Pages 55-63

  Tajouri, Tanya H ^a   Chareonthaitawee, Panithaya ^a  

^a MAYO CLINIC   (United States)

Author keywords

cardiac MRI; computed tomography; coronary artery disease; heart failure; imaging; ischemic cardiomyopathy; myocardial viability; PET; revascularization; single photon emission computed tomography

Indexed keywords

AMMONIA N 13; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM 201; TRACER;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LOW DRUG DOSE; MORTALITY; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL VIABILITY IMAGING; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT OUTCOME; CHRONIC DISEASE; COMPARATIVE STUDY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; METHODOLOGY; PATHOPHYSIOLOGY; STRESS ECHOCARDIOGRAPHY;

CHRONIC DISEASE; ECHOCARDIOGRAPHY, STRESS; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77949536671     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.157     Document Type: Review

References (51)

1. Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson L, Loscalzo J. Harrisons Principles of Internal Medicine (17th Edition). McGraw-Hill Companies, NY, USA (2008).
2. Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J. Am. Coll. Cardiol. 46, 567-574 (2005).
3. Alderman E, Fisher LD, Litwin P et al. Results of coronary artery surgery in patients with poor left ventricular dysfunction (CASS). Circulation 68, 785-795 (1983).
4. Bounous EP, Mark DB, Pollock BG et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 78(Suppl. I), I151-I157 (1988).
5. Velazquez EJ, Lee KL, O'Connor CM et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J. Thorac. Cardiovasc. Surg. 134, 1540-1547 (2007).
6. Cleland JG, Freemantle N, Ball SG et al. The heart failure revascularisation trial (HEART): rationale, design and methodology. Eur. J. Heart. Fail. 5, 295-303 (2003).
7. Jones RH, Vaelazquez EJ, Michler ME et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J. Med. 360, 1705-1717 (2009).
8. Mark DB, Knight JD, Velasquez EJ et al. Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. Am. Heart. J. 157, 837-844 (2009).
9. Coletta AP, Cleland JG, Cullington D, Clark AL. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008, ATHENA, URGENT, INH study, HEART and CK-1827452. Eur. J. Heart. Fail. 10, 917-920 (2008).
10. Bax JJ, van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 90(Suppl. V), V26-V33 (2004).
11. Cleland JGF, Pennell DJ, Ray SG et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 362, 14-21 (2003).
12. Galasko GIW, Lahiri A. The noninvasive assessment of hibernating myocardium in ischeaic cardiomyopathy-a myriad of techniques. Eur. J. Heart Fail. 5, 217-227 (2003).
13. Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr. Probl. Cardiol. 26, 141-186 (2001).
14. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur. J. Nucl. Med. 29, 1257-1266 (2002).
15. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr. Probl. Cardiol. 32, 375-410 (2007).
16. Santana CA, Shaw LJ, Garcia EV et al. Incremental prognostic value of left ventricular function by myocardial ECG-gated FDG PET imaging in patients with ischemic cardiomyopathy. J. Nucl. Cardiol. 11, 542-550 (2004).
17. Heller GV, Hendel R. Nuclear Cardiology: Practical Applications. McGraw-Hill Companies, NY, USA (2004).
18. Brunken RC, Mody FV, Hawkins RA, Nienaber C, Phelps ME, Schelbert HR. Positron emission tomography detects metabolic viability in myocardium with persistent 24-hour single-photon emission computed tomography 201Tl defects. Circulation 86, 1357-1369 (1992).
19. Sawada SG, Allman KC, Muzik O et al. Positron emission tomography detects evidence of viability in rest technetium- 99m sestamibi defects. J. Am. Coll. Cardiol. 23, 92-98 (1994).
20. Afridi I, Grayburn PA, Panza JA, Oh JK, Zoghbi WA, Marwick TH. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 32, 921-926 (1998).
21. Pagano D, Bonser RS, Townend JN, Ordoubadi F, Lorenzoni R, Camici PG. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 79, 281-288 (1998).
22. Klow NE, Smith HJ, Gullestad L, Seem E, Endresen K. Outcome of bypass surgery in patients with chronic ischemic left ventricular dysfunction. Predictive value of MR imaging. Acta Radiol. 38, 76-82 (1997).
23. Wu KC, Lima JAC. Noninvasive imaging of myocardial viability: current techniques and future developments. Circulation 93, 1146-1158 (2003).
24. Kim RJ, Wu E, Rafael A et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N. Engl. J. Med. 343, 1445-1453 (2000).
25. Maruskova M, Gregor P, Bartunek J, Tintera J, Penicka M. Myocardial viability and cardiac dyssynchrony as strong predictors of perioperative mortality in high-risk patients with ischemic cardiomyopathy having coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 138, 62-68 (2009).
26. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J. Am. Coll. Cardiol. 53, 1621-1628 (2009).
27. Gibbons RJ, Araoz PA, Williamson EE. The year in cardiac imaging. J. Am. Coll. Cardiol. 53, 54-70 (2009).
28. Lessick J, Ghersin E, Dragu R et al. Diagnostic accuracy of myocardial hypoenhancement on multidetector computed tomography in identifying myocardial infarction in patients admitted with acute chest pain syndrome. J. Comput. Assist. Tomogr. 31, 780-788 (2007).
29. Henneman MM, Schuijf JD, Dibbets- Schneider P et al. Comparison of multislice computed tomography to gated single- photon emission computed tomography for imaging of healed myocardial infarcts. Am. J. Cardiol. 101, 144-148 (2008).
30. Habis M, Capderou A, Ghostine S et al. Acute myocardial infarction early viability assessment by 64-slice computed tomography immediately after coronary angiography: comparison with low-dose dobutamine echocardiography. J. Am. Coll. Cardiol. 49, 1178-1185 (2007).
31. Chiou KR, Liu CP, Peng NJ et al. Identification and viability assessment of infarcted myocardium with late enhancement multidetector computed tomography: comparison with thallium single photon emission computed tomography and echocardiography. Am. Heart J. 155, 738-745 (2008).
32. Sato A, Hiroe M, Nozato T et al. Early validation study of 64-slice multidetector computed tomography for the assessment of myocardial viability and the prediction of left ventricular remodelling after acute myocardial infarction. Eur. Heart J. 29, 490-498 (2008).
33. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular systolic dysfunction: a meta-analysis. J. Am. Coll. Cardiol. 39, 1151-1158 (2002).
34. Di Carli MF, Davidson M, Little R et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am. J. Cardiol. 73:527-533(1994).
35. Anselmi M, Golia G, Cicoira M et al. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients. Am. J. Cardiol. 81, G21-G28 (1998).
36. Eitzman D, Al-Aquar Z, Kanter HL et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J. Am. Coll. Cardiol. 20, 559-565 (1992).
37. Pasquet A, Robert A, D'Hondt AM, Dion R, Melin JA, Vanoverschelde JL. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction. Circulation 100, 141-148 (1999).
38. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J. Am. Coll. Cardiol. 33, 1848-1854 (1999).
39. vom Dahl J, Altehoefer C, Sheehan FH et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J. Nucl. Med.
40. Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J. Am. Coll. Cardiol. 22, 984-997 (1993).
41. Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O'Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. Am. Heart J. 146 (2003).
42. Di Carli MF, Asgarzadie F, Schelbert HR et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 92, 3436-3444 (1995).
43. Gibbons RJ. Referral bias: a difficult but important topic. J. Nucl. Cardiol. 11, 117-1109 (2004).
44. Siebelink HM, Blanksma PK, Crijns HJ et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J. Am. Coll. Cardiol. 37, 81-88 (2001).
45. Beanlands RS, Nichol G, Huszti E et al. F18-Fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction. J. Am. Coll. Cardiol. 50, 2002-2012 (2007).
46. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee to update the 1999 guidelines for coronary artery bypass graft surgery). Circulation 110, 1168-1176 (2004).
47. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults a report of the American College of Cardiology Foundation/ American Heart Association task force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, E1-E90 (2009).
48. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 98, II51-II56 (1998).
49. Bax JJ, Schinkel AFL, Boersma E et al. Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome. Circulation 108(Suppl. II), II39-II42 (2003).
50. Miller WL, Tointon SK, Hodge DO, Nelson SM, Rodeheffer RJ, Gibbons RJ. Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects. Am. Heart J. 143, 904-909 (2002).
51. Kuhl HP, Lipke CS, Krombach GA et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography- single photon emission computed tomography imaging protocol. Eur. Heart J. 27, 846-853 (2006).